Science News
from research organizations

Study finds one treatment stands above others for adults with Langerhans cell histiocytosis

Date:
August 15, 2012
Source:
Baylor College of Medicine
Summary:
A physician-researcher has shed light on the most effective treatment for adults with Langerhans cell histiocytosis in bones.
Share:
       
FULL STORY

A study by a Baylor College of Medicine physician-researcher has shed light on the most effective treatment for adults with Langerhans cell histiocytosis in bones. LCH is a disease that can affect the skin, mouth, ears, bones, brain, gastrointestinal system, liver, spleen, or bone marrow.

In the study, appearing in the current issue of PLoS ONE, researchers reviewed health records for 58 adults with the disease and compared the effectiveness of three chemotherapy treatments vinblastine/prednisone, 2-Chlorodeoxyadenosine, and cytosine arabinoside.

"Cytarabine (cytosine arabinoside) is clearly the winner here ­it's the most effective and least toxic," said Dr. Ken McClain, professor of pediatrics ­hematology/oncology at BCM and director of the Histiocytosis Program at Texas Children's Cancer Center.

Little research

The study is important because LCH is rare in adults and there is very little research on the disease. There have been no studies in the literature up to now that compare different treatments, according to McClain.

"The number one thing that I hope comes out of this study is that physicians stop using vinblastine/prednisone, which is the least effective and most toxic chemotherapy treatment for this disease," he said.

Rare disease

LCH occurs when white blood cells called histiocytes and lymphocytes gather together and attack the skin, bones, brain, gastrointestinal system, major organs, mouth and ears. It affects children and adults and can range from a single skin lesion to multi-organ involvement. It can be chronic and debilitating and, in some cases, fatal.

The study reviewed patients who were seen from 2001 to 2011 at BCM. It offers data that could be useful for future clinical trials but, more importantly, it provides literature for physicians who do not know how to treat patients with this rare disease.


Story Source:

The above post is reprinted from materials provided by Baylor College of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Baylor College of Medicine. "Study finds one treatment stands above others for adults with Langerhans cell histiocytosis." ScienceDaily. ScienceDaily, 15 August 2012. <www.sciencedaily.com/releases/2012/08/120815174852.htm>.
Baylor College of Medicine. (2012, August 15). Study finds one treatment stands above others for adults with Langerhans cell histiocytosis. ScienceDaily. Retrieved July 5, 2015 from www.sciencedaily.com/releases/2012/08/120815174852.htm
Baylor College of Medicine. "Study finds one treatment stands above others for adults with Langerhans cell histiocytosis." ScienceDaily. www.sciencedaily.com/releases/2012/08/120815174852.htm (accessed July 5, 2015).

Share This Page: